A phase 2 study of GVAX colon vaccine with cyclophosphamide and pembrolizumab in patients with mismatch repair proficient advanced colorectal cancer

Phase 2 ◽

A Phase 2 Study of Intermittent High Dose Isophosphamide Therapy of Advanced Colorectal Cancer

Oncology ◽

10.1159/000224886 ◽

1974 ◽

Vol 29 (1) ◽

pp. 34-39 ◽

Cited By ~ 4

Author(s):

John S. Kovach ◽

Allan J. Schutt ◽

R.G. Hahn ◽

R.J. Reitemeier ◽

Charles G. Moertel

Keyword(s):

Colorectal Cancer ◽

High Dose ◽

Phase 2 ◽

Randomized phase 2 study of pegylated SN-38 (EZN-2208) or irinotecan plus cetuximab in patients with advanced colorectal cancer

Cancer ◽

10.1002/cncr.28358 ◽

2013 ◽

Vol 119 (24) ◽

pp. 4223-4230 ◽

Cited By ~ 23

Author(s):

Christopher R. Garrett ◽

Tanios S. Bekaii-Saab ◽

Theresa Ryan ◽

George A. Fisher ◽

Sally Clive ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase 2 ◽

Phase 2 Study ◽

Randomized Phase 2

A Randomized, Placebo-Controlled, Phase 2 Study of Efatutazone Maintenance Therapy in Patients with Advanced Colorectal Cancer Who Have Achieved Disease Control Following First-Line Chemotherapy

Annals of Oncology ◽

10.1093/annonc/mdu164.8 ◽

2014 ◽

Vol 25 ◽

pp. ii8

Author(s):

E. Boucher ◽

I. Davidenko ◽

D. Hadler ◽

R. von Roemeling ◽

G. Aprile

Keyword(s):

Colorectal Cancer ◽

Maintenance Therapy ◽

Disease Control ◽

Phase 2 ◽

First Line ◽

Phase 2 Study ◽

Line Chemotherapy

Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study

The Lancet Oncology ◽

10.1016/s1470-2045(17)30422-9 ◽

2017 ◽

Vol 18 (9) ◽

pp. 1182-1191 ◽

Cited By ~ 783

Author(s):

Michael J Overman ◽

Ray McDermott ◽

Joseph L Leach ◽

Sara Lonardi ◽

Heinz-Josef Lenz ◽

...

Keyword(s):

Colorectal Cancer ◽

Microsatellite Instability ◽

Mismatch Repair ◽

Dna Mismatch Repair ◽

Phase 2 ◽

Open Label ◽

Multicentre Phase ◽

Dna Mismatch ◽

Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial

The Lancet Gastroenterology & Hepatology ◽

10.1016/s2468-1253(21)00348-4 ◽

2021 ◽

Author(s):

Huabin Hu ◽

Liang Kang ◽

Jianwei Zhang ◽

Zehua Wu ◽

Hui Wang ◽

...

Keyword(s):

Colorectal Cancer ◽

Microsatellite Instability ◽

Mismatch Repair ◽

Locally Advanced Colorectal Cancer

Locally Advanced ◽

Phase 2 ◽

Single Centre ◽

Phase 2 Trial ◽

Parallel Group ◽

Phase 2 study of treatment selection based on tumor thymidylate synthase expression in previously untreated patients with metastatic colorectal cancer: A trial of the ECOG-ACRIN Cancer Research Group (E4203)

Cancer ◽

10.1002/cncr.30967 ◽

2017 ◽

Vol 124 (4) ◽

pp. 688-697

Author(s):

Neal J. Meropol ◽

Yang Feng ◽

Jean L. Grem ◽

Mary F. Mulcahy ◽

Paul J. Catalano ◽

...

Keyword(s):

Colorectal Cancer ◽

Cancer Research ◽

Metastatic Colorectal Cancer ◽

Thymidylate Synthase ◽

Research Group ◽

Treatment Selection ◽

Phase 2 ◽

Randomised phase 2 trial of SIR-Spheres® plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer

Journal of Surgical Oncology ◽

10.1002/jso.20141 ◽

2004 ◽

Vol 88 (2) ◽

pp. 78-85 ◽

Cited By ~ 297

Author(s):

Guy Van Hazel ◽

Anthony Blackwell ◽

James Anderson ◽

David Price ◽

Paul Moroz ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase 2 ◽

Phase 2 Trial

P-273 Hepatectomy followed by adjuvant chemotherapy with capecitabine plus oxaliplatin for three months for liver metastases from colorectal cancer: a multicenter phase 2 study

Annals of Oncology ◽

10.1093/annonc/mdw199.263 ◽

2016 ◽

Vol 27 ◽

pp. ii79

Author(s):

Satake Hironaga ◽

Tsuji Akihito ◽

Hashida Hiroki ◽

Tanioka Hiroaki ◽

Miyake Yasuhiro ◽

...

Keyword(s):

Colorectal Cancer ◽

Adjuvant Chemotherapy ◽

Liver Metastases ◽

Phase 2 ◽

Multicenter Phase ◽

Abstract 4461: Analysis of circulating tumor DNA (ctDNA) identifies on-treatment genomic alterations in a phase 2 study of veliparib plus FOLFIRI ± bevacizumab vs. placebo plus FOLFIRI ± bevacizumab in metastatic colorectal cancer (mCRC)

10.1158/1538-7445.sabcs18-4461 ◽

2019 ◽

Author(s):

Cyril Y. Ramathal ◽

Erin Murphy ◽

Elizabeth Asque ◽

Arne Jason Grundstad ◽

Peter Ansell ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Circulating Tumor Dna ◽

Phase 2 ◽

Genomic Alterations ◽

Phase 2 Study ◽

Tumor Dna

A phase 2 study of panitumumab with irinotecan as salvage therapy in chemorefractory KRAS exon 2 wild-type metastatic colorectal cancer patients

British Journal of Cancer ◽

10.1038/s41416-019-0537-z ◽

2019 ◽

Vol 121 (5) ◽

pp. 378-383 ◽

Cited By ~ 1

Author(s):

Elena Elez ◽

Carles Pericay ◽

Manuel Valladares-Ayerbes ◽

Inmaculada Bando ◽

Maria Jose Safont ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Cancer Patients ◽

Salvage Therapy ◽

Phase 2 ◽

Wild Type ◽

Exon 2 ◽

Phase 2 Study ◽

Colorectal Cancer Patients ◽

Kras Exon